Abstract:Background: Currently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.Methods: A total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.Results: Five protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.Conclusion: These results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI- TOF- MS is a potential tool for the screening of lung cancer.

The Application of MALDI-TOF MS in Mining Different Peptides and Proteins from the Sera of Lung-cancer Patients

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Identification of serum tumormarkers for diagnosing stage Ⅰ lung squamous cell carcinoma by MALDI-TOF mass spectrometry

Serum Peptidome Profiling in Patients with Lung Cancer.

Evaluation of Prostate Cancer Based on MALDI-TOF MS Fingerprinting of Nanoparticle-Treated Serum Proteins/peptides.

Application of MALDI-TOF-MS Technique to Screen the Serum Specific Protein in SHCC

Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology

[Detection of Serum Proteins in the Patients of Lung Adenocarcinoma by the Method of Magnetic Bead Based Sample Fractionation and MALDI-TOF-MS].

Screening of differentially expressed serum proteins of lung cancer by DIGE and MALDI-TOF MS/MS

MALDI Profiling MS Application to Analysis of Non-small Cell Lung Cancer

[Analysis of proteomic spectra in serum from patients with laryngeal carcinoma by SELDI-TOF-MS technology]

Study of Differential Proteins in Lung Adenocarcinoma Using Laser Capture Microdissection Combined with Liquid Chip-Mass Spectrometry Technology.

Application of Liquid Chip-Mass Spectrometry Technology for Screening Serum Biomarker Proteins in Lung Squamous Cell Carcinoma

Identification of Novel Low Molecular Weight Serum Peptidome Biomarkers for Non‐Small Cell Lung Cancer (NSCLC)

Application of Serum Surface-Enhanced Laser Desorption/ionization Proteomic Patterns in Distinguishing Lung Cancer Patients from Healthy People.

Differential Proteomic Analysis of Sera from Lung Squamous Carcinoma Patients and Healthy Subjects

Application of Serum Seldi Proteomic Patterns in Diagnosis of Lung Cancer

Comparative Proteome Analysis of Human Lung Squamous Carcinoma Using Two Different Methods: Two-Dimensional Gel Electrophoresis and Itraq Analysis

LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.

Analysis of Differentially Expressed Protein in Lung Tuberculosis Based on MB-MALDI-TOF-MS

Differential Protein Expression of Gastric Cancer and Liver Cancer in Serum Using Magnetic Bead Based Sample Fractionation and MALDI-TOF-MS